StockData
Phibro Animal Health Corp logo

Phibro Animal Health Corp (PAHC) stock

PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$35.57+0.65 (+1.86%)

Close on Nov 18, 2026Market cap $1.44BP/E 14.6Yield 1.35%

Phibro Animal Health r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $24.55M, up 3.5% from the year before. Over ten years it grew 8.3% a year on average. The highest annual figure on record is $29.19M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$24.55M+3.5%
FY2025Jun 30, 2025$23.73M-18.7%
FY2024Jun 30, 2024$29.19M+19.7%
FY2023Jun 30, 2023$24.40M+17.1%
FY2022Jun 30, 2022$20.83M+17.3%
FY2021Jun 30, 2021$17.76M+29.3%
FY2020Jun 30, 2020$13.74M+13.6%
FY2019Jun 30, 2019$12.09M+21.0%
FY2018Jun 30, 2018$10.00M+5.9%
FY2017Jun 30, 2017$9.44M-14.4%
FY2016Jun 30, 2016$11.03M+16.0%
FY2015Jun 30, 2015$9.51M+15.8%
FY2014Jun 30, 2014$8.21M+23.7%
FY2013Jun 30, 2013$6.64M-7.7%
FY2012Jun 30, 2012$7.19M–

More Phibro Animal Health figures

See a number that looks wrong?